Ocugen’s Chief Scientific Officer to Present at International Cell & Gene Therapy Meeting

Ocugen

MALVERN, PAOcugen, Inc. (NASDAQ: OCGN) announced that Arun Upadhyay, PhD, Chief Scientific Officer and Head of Research & Development, will speak at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting from May 29 to June 1, 2024, in Vancouver, Canada.

“I’m very pleased to present OCU400 data among an organization dedicated to translating cell and gene therapies into safe and effective treatments to improve patients’ lives,” said Dr. Upadhyay. “OCU400 modifier gene therapy represents a breakthrough approach for the potential treatment of broader retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) diseases where more than 100 mutations are involved.”

The ISCT meeting provides a platform for experts from academic institutions, regulatory agencies, and the healthcare industry to share cutting-edge research. Attendees can engage in debates, collaborate on solutions to sector challenges, and discuss advancements in cell and gene therapy.

Dr. Upadhyay will present during the Late-Breaking Oral Abstract Session on May 30, 2024, from 5-6 p.m. PDT. His presentation will cover safety and efficacy results from a Phase 1/2 clinical trial of OCU400 for treating retinitis pigmentosa. Additionally, his poster will be available during a networking session on May 29, 2024.

The OCU400 Phase 3 liMeliGhT clinical trial is progressing and aims to meet approval targets for 2026. This trial marks the first gene therapy program to enter Phase 3 with a broad RP indication.

Ocugen’s work highlights the growing importance of gene therapy in addressing complex genetic disorders. Treatments like OCU400 could revolutionize care for conditions with numerous mutations, offering hope to patients with limited options.

READ:  CMTA Invests $240K in Gene Therapy for Rare Nerve Disorder

However, the road to approval remains challenging. Regulatory scrutiny is intense, and companies must demonstrate both safety and efficacy in large patient populations. Success could pave the way for new therapies, but failure might hinder investment and slow progress in the field.

Ocugen’s presentation at ISCT will be closely watched by industry stakeholders. It represents a critical step in the company’s journey toward bringing innovative treatments to market. As the field of gene therapy evolves, such advancements hold the promise of transforming healthcare and improving patient lives.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.